Back to News
Market Impact: 0.12
Insilico Sees Rising Revenue From Deals With AI Firms
Source: Bloomberg
Artificial IntelligenceCompany FundamentalsAnalyst InsightsTechnology & Innovation
Bloomberg’s interview with Insilico Medicine CEO Alex Zhavoronkov focuses on the company’s AI-drug discovery business and its earnings/outlook. The provided excerpt is informational but does not include specific financial figures, guidance changes, or deal outcomes that would imply a clear positive or negative catalyst for markets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Musk says Terrafab chip factory could outperform rivals despite challenges
- CBO chief warns it’s ‘probably not plausible’ that a strong economy alone can steady U.S. debt as 5%-6% growth is needed—more than Bessent’s 3% view
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Stocks saw new highs and big declines: How the volatile AI trade moved last week's market
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant